4-N-(1-benzylpiperidin-4-yl)-2-N-[2-(dimethylamino)ethyl]quinazoline-2,4-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-N-(1-benzylpiperidin-4-yl)-2-N-[2-(dimethylamino)ethyl]quinazoline-2,4-diamine
• 化学式: C₂₄H₃₂N₆
• 分子量: 404.6
• InChiKey: KVELLWXBVJLZHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  56.3
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Cellular Compositions Used To Restore Stem Cell or Progenitor Cell Function and Methods Related Thereto
  申请人：Emory University

  公开号：US20170157178A1

  公开（公告）日：2017-06-08

  This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, methods of treating or preventing vascular or diabetic diseases or conditions are contemplated. In certain embodiments, epigenetically reprogramming adult bone marrow-derived stem or progenitor cells including mesenchymal stem cells (MSCs) or endothelial progenitor cells (EPCs) for autologous treatments are contemplated.

  这份披露涉及化合物、组合物和改变细胞表观遗传的方法。在某些实施例中，该披露涉及将孤立细胞与此处披露的组合物混合，在条件下使得表观遗传改变的细胞形成的方法。在某些实施例中，考虑了治疗或预防血管性或糖尿病性疾病或症状的方法。在某些实施例中，考虑了对成年骨髓来源的干细胞或祖细胞进行表观遗传重编程，包括间充质干细胞（MSCs）或内皮祖细胞（EPCs），用于自体治疗。
• Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
  申请人：Emory University

  公开号：US10828331B2

  公开（公告）日：2020-11-10

  This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, methods of treating or preventing vascular or diabetic diseases or conditions are contemplated. In certain embodiments, epigenetically reprogramming adult bone marrow-derived stem or progenitor cells including mesenchymal stem cells (MSCs) or endothelial progenitor cells (EPCs) for autologous treatments are contemplated.

  本公开涉及表观遗传转化细胞的化合物、组合物和方法。在某些实施方案中，本公开涉及产生表观遗传改变细胞的方法，包括在形成表观遗传改变细胞的条件下，将分离的细胞与本文公开的组合物混合。在某些实施方案中，考虑了治疗或预防血管或糖尿病疾病或病症的方法。在某些实施方案中，考虑了表观遗传重编程成人骨髓来源的干细胞或祖细胞，包括间充质干细胞（MSCs）或内皮祖细胞（EPCs），用于自体治疗。
• COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO
  申请人：Yoon Young-Sup

  公开号：US20140294764A1

  公开（公告）日：2014-10-02

  This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells, such as adult somatic cells or cells that are not naturally pluripotent, into cells with chemically induce pluripotency. In certain embodiments, the disclosure contemplates certain compounds disclosed herein, compounds disclosed herein optionally substituted with one or more substituents, derivatives, or salts thereof, for these purposes.
• US20150259649A1
  申请人：——

  公开号：US20150259649A1

  公开（公告）日：2015-09-17
• US9458131B2
  申请人：——

  公开号：US9458131B2

  公开（公告）日：2016-10-04